

Immunoterapia/Dati su TMB

- 4507 (Oral Presentation) [Preoperative pembrolizumab \(pembro\) before radical cystectomy \(RC\) for muscle-invasive urothelial bladder carcinoma \(MIUC\): Interim clinical and biomarker findings from the phase 2 PURE-01 study.](#)
- 12000 (Oral Presentation) [Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.](#)
- 11553 [Primary pulmonary sarcomas \(PSRC\): A comprehensive genomic profiling \(CGP\) study.](#)
- 11576 [Genomic subtypes of angiosarcoma: a comprehensive genomic profiling \(CGP\) study.](#)
- 4547 [APACHE: An open label, randomized, phase 2 study of durvalumab \(Durva\), alone or in combination with tremelimumab \(Treme\), in patients \(pts\) with advanced germ cell tumors \(GCT\): Results at the end of first stage.](#)
- 4531 [FGFR3 driven metastatic urothelial carcinoma of the urinary bladder \(mUCB\): A comprehensive genomic profiling study.](#)
- 4595 [PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab \(PEM\) and epacadostat \(EPA\), preceding radical cystectomy \(Cy\), for patients \(pts\) with muscle-invasive urothelial bladder cancer \(MIUBC\).](#)
- 4536 [Prognostic value of genomic alterations of DNA repair genes in advanced bladder cancer.](#)
- 11579 [Frequency of genomic biomarkers of response to immunotherapy in sarcoma.](#)
- 3574 [MSI-high and MSI-stable colorectal carcinomas \(CRC\): A comprehensive genomic profiling \(CGP\) Study.](#)
- 8562 [PBRM1 genomic alterations in mesothelioma: potential predictor of immunotherapy efficacy.](#)
- 12091 [PBRM1 mutation and immunotherapy efficacy: A comprehensive genomic profiling \(CGP\) assessment.](#)
- 12092 [PD-L1 genomic alterations \(GA\) in solid tumors and hematologic malignancies: A comprehensive genomic profiling \(CGP\) study.](#)
- 9587 [Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies.](#)

Dati sulla terapia personalizzata

- 5521 (Poster Discussion) [Genomic mutation profiles of paired ovarian cancers \(OC\) across time.](#)
- 1074 [Efficacy of olaparib monotherapy in patients \(pts\) with HER2-negative metastatic breast cancer \(MBC\) with germline BRCA mutation \(gBRCAm\) or lesional BRCA mutation \(lBRCAm\).](#)

- 4555 [Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors \(TGCT\).](#)
- 6089 [Comprehensive genomic profiling of anaplastic thyroid carcinoma.](#)
- 2039 [Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas.](#)
- 4063 [Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers \(EGC\): Analysis of 527 Her2-amplified cases.](#)
- 9035 [Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.](#)
- 2531 [Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy \(I-PREDICT\) in heavily pre-treated patients: A role for combinatorial precision cancer therapy.](#)
- 12083 [Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer \(NSCLC\).](#)
- 5590 [Assessment of activating estrogen receptor 1 \(ESR1\) mutations in gynecologic malignancies.](#)

Dati sulla biopsia liquida

- 9040 [Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations \(EGFRm\) using comprehensive genomic profiling \(CGP\).](#)
- 12041 [Landscape of kinase rearrangements \(kRE\) detected in circulating tumor DNA \(ctDNA\).](#)